Format

Send to

Choose Destination
Future Med Chem. 2019 Apr;11(8):847-855. doi: 10.4155/fmc-2018-0313. Epub 2019 Apr 17.

Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders.

Author information

1
Department of Surgery, Yale University School of Medicine, New Haven, CT 06520, USA.
2
Department of Cellular & Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA.

Abstract

Gastrointestinal illnesses pose a significant worldwide disease burden and are associated with an array of medicinal and surgical therapies. Standard pharmaceutical options have adverse effects, prompting the rise of nutraceutical or food-derivative therapies. Here, we present an overview of the current nutraceutical therapies in gastrointestinal disease. We then introduce the calcium-sensing receptor (CaSR) as a novel therapeutic target. A G-protein-coupled receptor found in apical and basal intestinal cells, the CaSR modulates intestinal fluid secretion and mucosal integrity. Applying nutraceuticals that upregulate the CaSR may alleviate symptoms seen across a spectrum of illnesses. At last, we discuss how nanoparticle technology can be implemented to effectively deliver nutraceuticals to diseased regions of the intestine, thereby minimizing systemic side effects.

KEYWORDS:

calcium-sensing receptor; gastrointestinal disorders; inflammation; nanoparticles; nutraceutical; pharmaceutical

PMID:
30994367
DOI:
10.4155/fmc-2018-0313

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center